Corneal graft failure – Diagnostics – Overview of Information and Clinical Research

Corneal graft failure is a serious concern for anyone who has received a corneal transplant, as it can cause the graft to lose its clarity and stop functioning properly. Understanding when and how to identify problems with a transplanted cornea can help protect your vision and guide timely treatment decisions.

Introduction: Who Should Undergo Diagnostics and When

Anyone who has undergone a corneal transplant should be regularly monitored to ensure their graft remains healthy and functional. Corneal graft failure refers to any situation where the transplanted cornea stops working properly and becomes cloudy, preventing clear vision. This can happen for many reasons, not all of which involve rejection by the body’s immune system.^[1]

Patients who have received a corneal transplant need to seek diagnostic evaluation if they experience certain warning signs. These include sudden or gradual vision loss, eye redness, pain, sensitivity to light, or any noticeable cloudiness in the eye. Even if symptoms seem mild at first, they should not be ignored, as early detection can make the difference between saving or losing a graft.^[2]

Regular follow-up appointments are essential for all transplant recipients, even when everything seems fine. Some patients are at higher risk than others. For example, those who have blood vessels growing into their cornea before surgery, those receiving a second or third transplant, or patients with certain underlying conditions face a greater chance of graft problems. These individuals need especially careful monitoring over time.^[1]

⚠️ Important

If you have had a corneal transplant and notice symptoms like decreased vision, redness, pain, or light sensitivity, contact your eye doctor immediately. Early diagnosis and treatment can often reverse rejection episodes and save the graft. Waiting even a few days may reduce the chances of successful treatment.

It is important to understand that graft failure and graft rejection are related but different concepts. Graft failure means the transplant is no longer functioning, which can result from immune rejection, but also from other causes such as infection, surgical complications, or gradual loss of the cells that keep the cornea clear. Graft rejection specifically refers to an immune attack by the recipient’s body against the donor tissue.^[12]

The timing of diagnostic evaluation matters greatly. In first-time transplant recipients who have healthy corneal beds without blood vessels, the success rate is very high, with more than 90 percent of grafts surviving at least two years. However, in patients with risk factors such as corneal blood vessel growth or previous failed transplants, this drops to between 35 and 70 percent. These statistics highlight why early and regular diagnostic monitoring is so important, especially for higher-risk patients.^[1]

Diagnostic Methods

Diagnosing corneal graft failure and rejection relies heavily on a thorough clinical examination by an eye care professional. The doctor will begin by asking detailed questions about symptoms, their onset, and their progression. This history helps distinguish between different types of problems that can affect a transplanted cornea.^[2]

The primary diagnostic tool is a careful eye examination using specialized equipment. The doctor will use a slit lamp, which is a microscope with a bright light that allows detailed viewing of the front structures of the eye. Through this instrument, the doctor can see signs of rejection or other problems affecting the graft. They will look for specific changes in the cornea’s appearance, including cloudiness, swelling, or abnormal deposits.^[13]

Several specific signs help doctors identify graft rejection during examination. One key finding is the presence of keratic precipitates, which are small white deposits of inflammatory cells on the inner surface of the cornea. When these deposits appear specifically on the transplanted tissue rather than on the patient’s own cornea, they strongly suggest rejection. The doctor will also check for corneal swelling, which causes the normally clear tissue to become cloudy and may create visible folds in one of the cornea’s inner layers.^[12]

Another important sign is redness around the edge of the cornea where it meets the white part of the eye. This limbal injection indicates inflammation and can accompany rejection episodes. The doctor will also look inside the eye for signs of inflammation in the anterior chamber, which is the fluid-filled space between the cornea and the colored iris. Cells floating in this normally clear fluid signal an immune response.^[13]

One finding that is especially telling is called a Khodadoust line. This appears as a distinct line on the cornea where white blood cells from the immune system are attacking the transplanted tissue. On one side of this line, the cornea appears swollen and cloudy, while on the other side it remains clear. This pattern is virtually diagnostic of endothelial rejection, which is the most common and serious form of graft rejection.^[12]

Doctors must also distinguish between different types of rejection, as each affects a different layer of the cornea. Epithelial rejection involves the outermost layer and appears as an elevated ridge or line at the edge of the graft that stains with fluorescein dye. Stromal rejection affects the middle layer and may show as small white infiltrates beneath the surface, sometimes resembling a viral eye infection. Endothelial rejection targets the critical inner cell layer that pumps fluid out of the cornea to keep it clear, and this type carries the greatest risk of permanent graft failure.^[13]

During the examination, the doctor will also measure the clarity of vision to assess how much the graft problem is affecting function. They will check eye pressure, as inflammation from rejection can sometimes alter this. The examination includes looking at the overall health of the eye surface, checking for signs of infection, and evaluating whether any other eye conditions might be contributing to symptoms.^[2]

Some doctors categorize endothelial rejection by severity to guide treatment decisions. A “possible” rejection shows mild signs that could have other causes. “Probable” rejection displays several characteristic features but might not have the most definitive signs. “Definite” rejection presents with clear, unmistakable evidence such as a Khodadoust line combined with multiple other findings. This classification helps determine how aggressively to treat the episode.^[12]

It is crucial to distinguish rejection from other causes of graft failure that are not immune-related. Problems like surgical complications, infection, disease of the eye surface, or simply the gradual loss of corneal cells over time can all make a graft fail without involving rejection. The doctor must carefully evaluate all possibilities, as the treatment differs depending on the underlying cause.^[12]

⚠️ Important

Not all cloudy corneal grafts mean rejection. Other problems like infection, inadequate tear production, or natural cell loss can cause similar symptoms. Your doctor must perform a complete examination to identify the true cause, as treatments differ significantly. Never assume the problem is rejection without proper diagnosis.

In some cases, particularly when the diagnosis is uncertain, additional testing may be helpful. The doctor might take samples of fluid from the eye’s surface or measure the density of cells on the inner corneal layer using specialized imaging. However, in most instances, a skilled clinical examination provides sufficient information to diagnose rejection and begin appropriate treatment promptly.^[2]

Diagnostics for Clinical Trial Qualification

Patients considering participation in clinical trials related to corneal transplantation or graft rejection prevention must undergo specific diagnostic evaluations to determine their eligibility. These assessments are more detailed than routine follow-up examinations and are designed to ensure that trial participants meet precise criteria defined by researchers.^[9]

Clinical trials typically require comprehensive documentation of the patient’s transplant history. This includes recording the type of transplant performed, whether it was a full-thickness penetrating keratoplasty or a partial-thickness procedure like endothelial keratoplasty. The reason for the original transplant, the number of previous grafts if any, and the presence of risk factors such as corneal blood vessels must all be carefully documented.^[10]

Visual acuity testing forms a baseline measurement for trials. Researchers need to know exactly how well each participant sees before any experimental intervention begins. This allows them to measure whether a new treatment improves, maintains, or fails to affect vision outcomes. The testing uses standardized charts and protocols to ensure consistency across all participants and study sites.^[9]

Detailed examination of the corneal graft is essential for trial enrollment. Doctors must document the current clarity of the graft, the presence or absence of rejection signs, and the health of the endothelial cell layer. Some trials use specialized imaging equipment to count the number of cells on the inner corneal surface, as this number correlates with graft function and survival. The density of these cells naturally decreases after transplantation, and trials may only accept participants whose cell counts fall within specific ranges.^[2]

Assessment of risk factors is particularly important for trials testing rejection prevention strategies. Researchers categorize patients as “low risk” or “high risk” based on several factors. High-risk features include the presence of blood vessels in the cornea before transplantation, a history of previous graft failure, certain inflammatory eye conditions, and the presence of glaucoma drainage devices. Trials may specifically recruit high-risk patients to test whether new treatments can improve outcomes in this challenging group.^[1]

Some clinical trials require laboratory testing beyond the eye examination. This might include blood tests to check overall health, kidney and liver function tests if the trial involves systemic medications, or immune system assessments to understand each participant’s baseline immunological status. These tests help researchers understand how different patients respond to treatments and identify any safety concerns.^[9]

Documentation of current medications is crucial for trial qualification. Patients taking certain immunosuppressive drugs or corticosteroids may be excluded from some trials, as these medications could interfere with study results. Conversely, some trials specifically study patients already on particular treatment regimens. Complete medication histories ensure that researchers can properly interpret trial outcomes.^[9]

Follow-up examination schedules in clinical trials are typically more frequent and standardized than in regular clinical care. Participants may need to attend appointments at specific intervals, such as weekly or monthly, for detailed assessments. These examinations use consistent protocols to track changes in graft appearance, visual function, and the development of any rejection episodes. This rigorous monitoring allows researchers to detect treatment effects and complications early.^[9]

Some trials investigating new treatments for preventing or reversing rejection require biopsy procedures or other invasive tests that would not be part of routine care. Participants must understand these requirements and the associated risks before enrolling. The informed consent process ensures that patients make educated decisions about trial participation based on full knowledge of what diagnostic procedures will be required.^[9]

Imaging studies beyond standard slit lamp examination may be required in certain trials. Advanced techniques like confocal microscopy, which provides extremely detailed views of corneal cell layers, or optical coherence tomography, which creates cross-sectional images of corneal structure, might be used to precisely measure treatment effects. These sophisticated technologies allow researchers to detect subtle changes that might not be visible with conventional examination methods.^[2]

Quality of life assessments often form part of clinical trial diagnostics. Researchers use standardized questionnaires to measure how corneal problems affect daily activities, emotional well-being, and overall life satisfaction. These patient-reported outcomes complement clinical measurements and help determine whether new treatments provide meaningful benefits beyond just technical improvements in graft appearance.^[10]

Prognosis and Survival Rate

Prognosis

The outlook for corneal transplant patients depends heavily on several factors that can be assessed at the time of surgery and during follow-up care. Patients receiving their first corneal transplant who have healthy corneal beds without blood vessel growth enjoy excellent prognosis, with very high success rates. However, the presence of certain risk factors significantly affects long-term outcomes.^[1]

When rejection episodes occur, prompt treatment is critical to prognosis. Studies show that the timing of intervention matters greatly, with patients seeking care within the first week of symptoms having better outcomes than those who delay. However, even with appropriate treatment, rejection episodes increase the risk of eventual graft failure. The severity of the rejection, the type of tissue involved, and how quickly the graft responds to therapy all influence the final outcome.^[7]

Patients who experience one rejection episode face elevated risk for future episodes and long-term graft failure. Research indicates that following a rejection event, up to one-third of grafts will fail within six months. This underscores the importance of ongoing vigilance even after successfully treating rejection. Multiple rejection episodes progressively damage the critical endothelial cell layer, which cannot regenerate once lost.^[12]

The type of transplant procedure influences prognosis. Partial-thickness transplants like endothelial keratoplasty generally have lower rejection rates compared to full-thickness penetrating keratoplasty. However, the specific diagnosis and patient factors often determine which procedure is most appropriate, rather than rejection risk alone driving the decision.^[2]

Factors that worsen prognosis include extensive corneal blood vessel growth, glaucoma requiring drainage devices, severe inflammation, history of chemical burns, and receiving second or subsequent transplants. Each previous failed graft substantially reduces the chance of success with the next transplant, with survival rates for third grafts dropping to about 25 percent and fourth grafts having almost no chance of long-term success.^[9]

Survival Rate

In first-time graft recipients with no blood vessel growth in the corneal bed, two-year survival rates exceed 90 percent. This means more than nine out of ten such patients will have a clear, functioning graft two years after surgery. These excellent outcomes reflect the cornea’s special immune-privileged status and modern surgical techniques.^[1]

However, survival rates drop dramatically in patients with high-risk factors. For these individuals, two-year survival rates range from only 35 to 70 percent. This wide range reflects the varying combinations and severity of risk factors different patients bring to surgery. The presence of blood vessels in particular significantly compromises outcomes, as these provide highways for immune cells to reach and attack the transplanted tissue.^[1]

Overall graft survival rates for penetrating keratoplasty reported in various studies range from 52 to nearly 99 percent, depending on the patient population studied, length of follow-up, and specific definitions used. At five years, data from major studies show that about 23 percent of patients experience at least one rejection episode, and among those who do, 37 percent eventually develop graft failure.^[2]

Long-term survival data reveals that in approximately one-third of all corneal grafts that ultimately fail, signs of immune system attack can be identified as the cause. This makes rejection the single most common reason for corneal transplant failure across all studies. The other two-thirds of failures result from non-immunological causes such as primary graft failure, infection, glaucoma, or recurrence of the original disease.^[1]

For partial-thickness transplants, reported survival rates are generally higher. Deep anterior lamellar keratoplasty shows success rates ranging from 77 to over 99 percent, with rejection rates between 6 and 20 percent. Endothelial keratoplasty procedures also demonstrate lower rejection rates compared to full-thickness transplants, though these procedures are only suitable for certain types of corneal disease affecting the inner cell layer.^[2]

The statistics emphasize that corneal transplantation remains highly successful for appropriate patients, particularly those without major risk factors. However, they also highlight the ongoing challenge of rejection and the importance of careful patient selection, surgical technique, and long-term monitoring to maximize graft survival rates.^[2]

#1 Clinical Trials Search in Europe